Emergent BioSolutions receives FDA approval for raxibacumab manufacturing at Winnipeg site

Emergent BioSolutions Inc.

FDA approved sBLA for Winnipeg as drug product manufacturing and testing site for raxibacumab.
Raxibacumab is a monoclonal antibody for treatment and prophylaxis of inhalational anthrax.
Approval supports multi-year turnaround strategy to consolidate manufacturing in Winnipeg and Lansing.
Winnipeg facility has over 45 years experience in commercial therapeutics manufacturing.
CEO Joe Papa says this regulatory action advances flexible, streamlined manufacturing network.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.